The themes Assembly Biosciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Built from Assembly Biosciences, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$21.15+4.6%Nov 13 close
The latest quarter (ended September 30, 2026) is from Assembly Biosciences’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once Assembly Biosciences files it.
Grade B-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 31 quarters of Assembly Biosciences, Inc.’s grade history. The other 29 go back to February 2019.